CN118139849A - 四元稠环类化合物及其制备方法和应用 - Google Patents

四元稠环类化合物及其制备方法和应用 Download PDF

Info

Publication number
CN118139849A
CN118139849A CN202280064600.7A CN202280064600A CN118139849A CN 118139849 A CN118139849 A CN 118139849A CN 202280064600 A CN202280064600 A CN 202280064600A CN 118139849 A CN118139849 A CN 118139849A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280064600.7A
Other languages
English (en)
Chinese (zh)
Inventor
王霄
丁小华
陈国辉
孙运栋
王小雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN118139849A publication Critical patent/CN118139849A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/22—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202280064600.7A 2021-09-30 2022-09-29 四元稠环类化合物及其制备方法和应用 Pending CN118139849A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111161691X 2021-09-30
CN202111161691 2021-09-30
PCT/CN2022/122536 WO2023051681A1 (zh) 2021-09-30 2022-09-29 四元稠环类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN118139849A true CN118139849A (zh) 2024-06-04

Family

ID=85781355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280064600.7A Pending CN118139849A (zh) 2021-09-30 2022-09-29 四元稠环类化合物及其制备方法和应用

Country Status (11)

Country Link
US (1) US20240400582A1 (https=)
EP (1) EP4410779A4 (https=)
JP (1) JP2024534707A (https=)
KR (1) KR20240089224A (https=)
CN (1) CN118139849A (https=)
AU (1) AU2022355393A1 (https=)
CA (1) CA3234312A1 (https=)
IL (1) IL311791A (https=)
MX (1) MX2024004025A (https=)
TW (1) TW202330547A (https=)
WO (1) WO2023051681A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
CN103113355B (zh) * 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
CN109790144A (zh) * 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
US11649218B2 (en) * 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Also Published As

Publication number Publication date
MX2024004025A (es) 2024-05-31
EP4410779A4 (en) 2025-07-30
TW202330547A (zh) 2023-08-01
IL311791A (en) 2024-05-01
WO2023051681A1 (zh) 2023-04-06
AU2022355393A1 (en) 2024-05-09
CA3234312A1 (en) 2023-04-06
US20240400582A1 (en) 2024-12-05
JP2024534707A (ja) 2024-09-20
EP4410779A1 (en) 2024-08-07
KR20240089224A (ko) 2024-06-20

Similar Documents

Publication Publication Date Title
CN113179640B (zh) 含氮多环类衍生物抑制剂、其制备方法和应用
CN112292378B (zh) 含吲哚类衍生物抑制剂、其制备方法和应用
TWI765908B (zh) 苯並咪唑類化合物激酶抑制劑及其製備方法和應用
CN112079830B (zh) 含并环类衍生物抑制剂、其制备方法和应用
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
ES2415863T3 (es) Heterociclos sustituidos como inhibidores de Janus Quinasas
CN113348170B (zh) 联苯类衍生物抑制剂、其制备方法和应用
ES2697697T3 (es) Compuestos de pirimidina y piridina novedosos y su uso
BR122023006150B1 (pt) Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende
JP6200520B2 (ja) 置換２−アミノピリジンプロテインキナーゼ阻害剤
KR20190141215A (ko) N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법
TW202317564A (zh) Cdk2抑制劑及其製備方法和用途
CN118055933B (zh) 选择性parp1抑制剂及其应用
JP2016028045A (ja) Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物
JP2007534624A (ja) ビアリールピペラジニル−ピリジン類縁体
TW202144369A (zh) 海鞘素類衍生物及其製備方法與醫藥用途
CN118139849A (zh) 四元稠环类化合物及其制备方法和应用
TW202136259A (zh) 聯苯類衍生物抑制劑及其製備方法和應用
HK40051502A (en) Nitrogen-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
HK40036077A (en) Indole derivative-containing inhibitor, preparation method therefor and application thereof
HK40003421B (en) Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof
HK40003421A (en) Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110454

Country of ref document: HK